Whittier Trust’s Phathom Pharmaceuticals PHAT Stock Holding History

Whittier Trust’s Portfolio PHAT Stock Details PHAT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-33	Closed	-$369	–	1632
2022 Q4	$369	Buy	+33	New	+$340	﹤0.01%	1587

Other funds holding PHAT

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return

MVM

Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

Whittier Trust's PHAT Position: Q1 2023 in Review

Whittier Trust sold out of Phathom Pharmaceuticals (PHAT) in Q1 2023, closing a stake of 33 shares — an estimated $369 sold.

Whittier Trust first reported a position in PHAT in Q4 2022 and held it in 1 quarter. The position peaked at $369 in Q4 2022. 84 funds tracked by Wall St. Rank hold PHAT as of Q1 2023.

Whittier Trust reported no remaining Phathom Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Whittier Trust sold 33 Phathom Pharmaceuticals shares in Q1 2023, an estimated $369.
Whittier Trust first reported a position in Phathom Pharmaceuticals in Q4 2022 and held it in 1 quarter.
Whittier Trust's Phathom Pharmaceuticals position peaked at $369 in Q4 2022.
84 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q1 2023.

Based on Whittier Trust's 13F filing for Q1 2023, filed 21 Apr 2023.